Clinical Efficacy Analysis Of Glucocorticoid On Primary Endocardial Fibroelostosis In Children

Objective: To study the clinical efficacy of glucocorticoid in the treatment of endocardial fibroelastosis(EFE).Methods: Selecting 58 EFE cases which were admitted into Children's Hospital of Chongqing Medical University from January 2006 to December 2013,their treatments were followed-up for more than 3 years.According to the time of glucocorticoid therapy,cases were divided into three groups: not application glucocorticoid group,application glucocorticoid 0.5 to 1 year group and application glucocorticoid 1 to 2 years group.Following & analyzing the cardiac function indexes before and after treatment(Modified Ross score,left ventricular ejection fraction(LVEF),left ventricular fractional shortening(LVFS)),cardiac size(cardiothoracic ratio(C/T))and the proportion of deaths.The efficacy and safety of glucocorticoid were studied.Results: There were no significant difference(p>0.05)of the onset age,modified ROSS score,LVEF,LVFS and the C/T among the three groups.After treatment,the date of three groups are: the modified of ROSS score(6.00±1.48,2.06±1.78,1.28±1.54),LVEF(42.91±14.36,59.29±8.34,64.64 ± 9.08),LVFS(21.55±8.63,31.24±6.0,35.44±5.44),C/T(0.628±0.049?0.580 ± 0.055?0.573±0.05),the proportion of deaths(26.67%,0,3.84%).There is statistically significant difference before and after the treatment in application glucocorticoid 0.5 to 1 years group and 1~2 years group(p < 0.05)on the modified ROSS score,LVEF,LVFS and the C/T.However,no significant difference was found between application glucocorticoid 0.5 ~1 years group and 1 ~2 years group(p < 0.05),on the modified ROSS score,LVEF,and the C/T after the treatment.Conclusion: The immunotherapy of glucocorticoid has good clinical effect on endocardial fibroelastosis,and it is effective for six months to 1 year,The total course of glucocorticoid therapy six months to 1 year is not significantly different with 1 to 2 years.